PJP - ETF AI Analysis
Top Page
Invesco Dynamic Pharmaceuticals ETF (PJP)
Rating:69Neutral
Price Target:―
Positive Factors
Strong Large-Cap Pharma Holdings
Several major drug companies in the top holdings have shown strong gains this year, helping support the fund’s overall performance.
Focused Healthcare Exposure
The ETF is heavily concentrated in the health care sector, giving investors targeted exposure to pharmaceutical and biotech companies.
Solid Recent Momentum
The fund has delivered steady gains over the past month and year to date, indicating improving short-term performance.
Negative Factors
High Sector Concentration
Almost all assets are in the health care sector, so the fund could be hit hard if pharmaceutical stocks fall out of favor.
Limited Geographic Diversification
With nearly all holdings in U.S. companies, the ETF offers little protection if the U.S. market or regulatory environment turns negative for drug makers.
Relatively High Expense Ratio
The fund’s expense ratio is on the higher side for an ETF, which can gradually reduce net returns for long-term investors.
PJP vs. SPDR S&P 500 ETF (SPY)
AUM326.78M
RegionNorth America
Expense Ratio0.57%
Beta0.59
IssuerInvesco
Inception DateJun 23, 2005
Dividend Yield1%
Asset ClassEquity
Index TrackedDynamic Pharmaceutical Intellidex Index (AMEX)
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume9,966
30 Day Avg. Volume25,407
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
138.99Price Target Upside― Downside
Rating ConsensusStrong Buy
Number of Analyst Covering30
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PJP Summary
The Invesco Dynamic Pharmaceuticals ETF (PJP) is a fund that focuses on U.S. drugmakers by tracking the Dynamic Pharmaceutical Intellidex Index. It holds a basket of major pharmaceutical companies, including well-known names like Pfizer and Johnson & Johnson. Investors might consider PJP if they want targeted exposure to the health care and drug industry, which can benefit from an aging population and ongoing demand for new medicines, while still spreading money across many companies. A key risk is that it is heavily concentrated in one sector, so its price can swing with news about drug approvals, regulations, and health care policy.
How much will it cost me?The Invesco Dynamic Pharmaceuticals ETF (PJP) has an expense ratio of 0.57%, meaning you’ll pay $5.70 per year for every $1,000 invested. This cost is higher than average because it’s actively managed, focusing on selecting pharmaceutical stocks based on various strategic factors to optimize performance.
What would affect this ETF?The Invesco Dynamic Pharmaceuticals ETF (PJP) could benefit from advancements in drug discovery, regulatory approvals, and the growing demand for pharmaceuticals driven by an aging population. However, it may face challenges from stricter regulations, patent expirations, or pricing pressures in the U.S. market, where it is heavily focused. The performance of its top holdings, such as AbbVie and Eli Lilly, will also play a significant role in shaping its future returns.
PJP Top 10 Holdings
PJP is a pure U.S. pharma play, and its story right now is a tug-of-war between steady giants and fast-moving niche players. Blue chips like Pfizer, Johnson & Johnson, Merck, and Amgen are providing a relatively stable backbone, with generally rising or steady trends that keep the fund from wobbling too much. On the flip side, former stars AbbVie, Eli Lilly, and especially Abbott are losing steam and acting as a drag. Meanwhile, smaller names like Travere and Corcept are sprinting ahead, giving the ETF a shot of high-octane growth risk within a very concentrated health care theme.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Pfizer | 4.96% | $16.51M | $144.37B | 10.13% | 74 Outperform | |
| Eli Lilly & Co | 4.95% | $16.47M | $946.37B | 30.85% | 72 Outperform | |
| Liquidia Technologies | 4.86% | $16.17M | $5.06B | 234.53% | 57 Neutral | |
| Gilead Sciences | 4.75% | $15.83M | $160.88B | 22.14% | 78 Outperform | |
| Johnson & Johnson | 4.74% | $15.78M | $545.74B | 50.12% | 78 Outperform | |
| AbbVie | 4.73% | $15.76M | $371.72B | 12.76% | 66 Neutral | |
| Merck & Company | 4.72% | $15.70M | $275.09B | 45.75% | 80 Outperform | |
| Amgen | 4.57% | $15.21M | $176.11B | 17.60% | 77 Outperform | |
| Corcept Therapeutics | 4.04% | $13.45M | $6.05B | -26.33% | 76 Outperform | |
| Travere Therapeutics | 4.00% | $13.31M | $3.96B | 152.14% | 56 Neutral |
PJP Technical Analysis
Positive
―
Price Trends
104.20
Positive
105.38
Positive
100.43
Positive
Market Momentum
0.50
Positive
51.86
Neutral
15.14
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PJP, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 105.65, equal to the 50-day MA of 104.20, and equal to the 200-day MA of 100.43, indicating a bullish trend. The MACD of 0.50 indicates Positive momentum. The RSI at 51.86 is Neutral, neither overbought nor oversold. The STOCH value of 15.14 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PJP.
PJP Peer Comparison
Comparison Results
Performance Comparison
PJP
Invesco Dynamic Pharmaceuticals ETF
106.10
28.10
36.03%
IHE
iShares U.S. Pharmaceuticals ETF
―
―
―
FXH
First Trust Health Care AlphaDEX Fund
―
―
―
IHF
iShares U.S. Healthcare Providers ETF
―
―
―
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
―
―
―
XPH
SPDR S&P Pharmaceuticals ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents